378 related articles for article (PubMed ID: 21034423)
1. Radioimmunotherapy of solid tumors: searching for the right target.
Song H; Sgouros G
Curr Drug Deliv; 2011 Jan; 8(1):26-44. PubMed ID: 21034423
[TBL] [Abstract][Full Text] [Related]
2. General overview of radioimmunotherapy of solid tumors.
Navarro-Teulon I; Lozza C; Pèlegrin A; Vivès E; Pouget JP
Immunotherapy; 2013 May; 5(5):467-87. PubMed ID: 23638743
[TBL] [Abstract][Full Text] [Related]
3. Clinical radioimmunotherapy--the role of radiobiology.
Pouget JP; Navarro-Teulon I; Bardiès M; Chouin N; Cartron G; Pèlegrin A; Azria D
Nat Rev Clin Oncol; 2011 Nov; 8(12):720-34. PubMed ID: 22064461
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
Macklis RM; Pohlman B
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
6. Current concepts and future directions in radioimmunotherapy.
Lin FI; Iagaru A
Curr Drug Discov Technol; 2010 Dec; 7(4):253-62. PubMed ID: 21034409
[TBL] [Abstract][Full Text] [Related]
7. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of lymphoma: Bexxar and Zevalin.
Goldsmith SJ
Semin Nucl Med; 2010 Mar; 40(2):122-35. PubMed ID: 20113680
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
Jacene HA; Filice R; Kasecamp W; Wahl RL
J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
[TBL] [Abstract][Full Text] [Related]
10. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.
Goldenberg DM
Crit Rev Oncol Hematol; 2001; 39(1-2):195-201. PubMed ID: 11418316
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Kawashima H
ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
[TBL] [Abstract][Full Text] [Related]
13. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
[TBL] [Abstract][Full Text] [Related]
14. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
Hernandez MC; Knox SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):6-10. PubMed ID: 14710397
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
Ghobrial I; Witzig T
Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
[TBL] [Abstract][Full Text] [Related]
16. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar.
Sachpekidis C; Jackson DB; Soldatos TG
Pharmaceuticals (Basel); 2019 Sep; 12(4):. PubMed ID: 31546999
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.
Theuer CP; Leigh BR; Multani PS; Allen RS; Liang BC
Biotechnol Annu Rev; 2004; 10():265-95. PubMed ID: 15504711
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
Macklis RM
Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
